[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-transplant-infection-prevention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-transplant-infection-prevention":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100607936",false,"NCT07195032","Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients","Inclusion Criteria:\n\n* Received a heart transplant\n* At least 1 year after transplant\n* At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)\n* At least 1 year from anti-thymocyte globulin\n* At least 6 months after pulse dose steroid treatment or basiliximab treatment\n* No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion\n* Clinically well\n\nExclusion Criteria:\n\n* History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.\n* History of anaphylactic reaction to MMR vaccination","ALL","1 Year","17 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission\u002Fassent will receive the commercial MMR vaccine according to product indication and labeling.",[25],"Heart Transplant Infection Prevention",[27,28,29,30,31],"Measles","Mumps","Rubella","Live vaccine","Heart transplant","RECRUITING","2025-09-19",{"date":35,"type":36},"2025-09-26","ACTUAL",{"date":38,"type":36},"2025-09-11",{"date":40,"type":19},"2027-09-11",{"name":42,"class":43},"Children's Mercy Hospital Kansas City","OTHER",""]